Tirzepatide vs. 'retaturide': sorting real science from TikTok claims

What's this video probably claiming?

Based on the caption, this creator is making a head-to-head comparison between tirzepatide and something called "retaturide," arguing tirzepatide is the superior drug. The caption mentions tirzepatide's dual GIP/GLP-1 receptor agonism as a selling point. Given the account name (@glutidefacts) and the peptide category tag, the video is almost certainly aimed at an audience already familiar with GLP-1 medications, possibly people researching compounded tirzepatide. The framing of "superior option" suggests a recommendation is being made, which on TikTok, without clinical context, is a significant red flag. The truncated caption also suggests the creator may be expanding into efficacy comparisons, side effect profiles, or weight loss percentages. Whether the comparison is grounded in peer-reviewed trial data or influencer interpretation of press releases is exactly what needs scrutiny here.

What does the science actually show?

Tirzepatide's dual GIP and GLP-1 receptor activity is real and well-documented. The SURMOUNT-1 trial (Jastreboff et al., 2022, NEJM) showed tirzepatide at 15mg produced a mean body weight reduction of 20.9% over 72 weeks in adults with obesity, no diabetes. That's a genuinely significant number. Semaglutide 2.4mg, by comparison, showed roughly 14.9% in the STEP-1 trial (Wilding et al., 2021, NEJM). As for "retaturide," this appears to be retatrutide, a triple agonist targeting GIP, GLP-1, and glucagon receptors, developed by Eli Lilly. Phase 2 data (Jastreboff et al., 2023, NEJM) showed retatrutide at 12mg produced up to 24.2% weight loss at 48 weeks. That means the "superior" framing in the caption may actually have the comparison backwards. Retatrutide is not yet FDA-approved and is not the same as tirzepatide.

Where does the social media noise diverge from clinical reality?

Several likely distortions are worth calling out directly. First, calling tirzepatide "superior" to retatrutide based on current data is hard to justify. Retatrutide's Phase 2 numbers are larger in magnitude, though head-to-head trials don't yet exist and Phase 2 data is not Phase 3 data. Second, the peptide category tag on this video is a category error. Tirzepatide and retatrutide are synthetic peptide-based drugs that are FDA-regulated as new molecular entities, not research peptides like BPC-157 or TB-500. Conflating these categories misleads viewers about legal status, safety data, and regulatory oversight. Third, efficacy comparisons between compounded tirzepatide and brand-name Zepbound or Mounjaro are not legitimate. Compounded versions lack bioequivalence data. Claiming otherwise would violate FDA guidance and basic pharmacology.

What should you actually know?

Tirzepatide is a real, FDA-approved medication with strong clinical trial backing for type 2 diabetes (Frías et al., 2021, NEJM, SURPASS-2) and obesity (SURMOUNT-1). Retatrutide is a promising investigational drug, not an approved therapy, and its trial data actually suggests stronger weight loss outcomes than tirzepatide in early comparisons, though that comparison is premature without Phase 3 and head-to-head data. Neither drug should be evaluated through a TikTok caption. If you're considering either medication, the relevant questions are: Is it FDA-approved for your indication? Does your prescriber have access to your full health history? Are you being offered brand-name or compounded product, and do you understand the legal and quality differences? A 40,000-view TikTok is not a substitute for a clinical consultation with someone who has reviewed your labs.